grey
space
About Us
      Technology      Investors      News / Events      Careers      Contact
Advanced Proteome Therapeutics - Enhancing Protein Therapeutics Through Selective Modification Advanced Proteome Therapeutics - Enhancing Protein Therapeutics Through Selective Modification
space
space
NEWS
 
space

November 12, 2014
Advanced Proteome Therapeutics Engages CRO to Escalate Testing of Promising Cancer Therapy
more...
 

September 11, 2014
APC Announces Positive Results in Combination Cancer Immunotherapy.
more...
 

August 12, 2014
Advanced Proteome Therapeutics Expands Anticancer Studies Based on Strong Initial Results
more...
 
space

TSX-V: APC

Advancing Targeted Therapies Using The Foundation Trinity™
                     Technology in the War on Cancer


Advanced Proteome Therapeutics has developed a patent-pending technology that combines multiple anti-cancer therapies in a single agent to directly target cancer tumors. This type of agent, carrying multiple anti-cancer therapies, has exhibited greater potency, higher specificity, and less toxicity than individual therapies that can also attack healthy cells.

Our technology is based on a proprietary protein modification platform that can be used to attach entities to therapeutic proteins to enhance their properties and/or endow them with additional functions. Overall, our proprietary technology is based on "The Foundation Trinity™", which utilizes targeted therapy, combination therapy, and immunotherapy, in a single agent of high purity. Advanced, targeted therapies such as ours are intended to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics market in the near future.


CEO-CFO-logo

CEO CFO Magazine Report
Advanced Proteome Therapeutics Corp is focused on developing a Protein Therapeutic that is Targeted and Combines Multiple Anti-Cancer Therapies for Greater Potency,
Higher Specificity and Less Toxicity than Individual Therapies
Read more..

Targeted Cancer Therapeutics and Immunotherapy
A 4 minute video interview with Dr. Allen Krantz and a visit to the company's lab.



Disclaimer






space
 
Website and branding by NextPhase Strategy